湖北省HIV-1流行株gag基因序列测定及亚型分析

目的 了解湖北省HIV-1感染者流行毒株亚型分布和流行趋势.方法 随机采集湖北省HIV-1感染者的抗凝全血标本,分离血浆,提取病毒RNA,用套式聚合酶链反应扩增HIV-1病毒gag基因,并进行序列测定和亚型分析.结果 对80份HIV-1感染者的样品进行扩增,得到了62份样品的HIV-1基因片段.共发现7种HIV-1亚型和流行重组株.泰国B'亚型占11.3％ (7/62),欧美B亚型占4.8％ (3/62),G亚型占4.8％ (3/62),CRF07-BC占22.6％ (14/62),CRF08-BC占6.5％(4/62),CRF01-AE占48.4％(30/62),CRF15-01B占1.6％ (1/62).在湖北省发现了CRF15-01B和G亚型.结论 湖北省存在多种HIV-1亚型和流行重组型,CRF01-AE、CRF07-BC两种重组亚型毒株为目前湖北省HIV-1流行优势毒株,应加强对HIV-1毒株亚型变异的监测,及时调整防治策略.     

相同来源HIV-1 Env、Gag基因序列变异和宿主基因多态性与疾病进展关系的分析

目的探讨HIV—1基因序列变异和宿主基因多态性与疾病进展的关系。方法PCR方法从外周血细胞中扩增HIV—1 Env、Gag区片段和测序，分析序列变异、糖基化，超突变等指标。RFLP法确定宿主基因多态性。结果未治疗组中，env基因区PCR和克隆序列平均离散率分别为0．1和0．06，差异有统计学意义，治疗组内差异没有统计学意义。V3环顶端序列在未治疗和治疗组中均以GPGQ比例最大（61．5％和39％），治疗组出现稀有多肽序列如GPGH、GQGR、GLGR、12位I／V和21位Y／H变异与疾病快速进展相关。Env区段上进展较快速组（RRP）比典型进展组（TP）的糖基化程度高（平均值分别为14．56和13．20个），差异有统计学意义。Env区段上RRP比TP组GA取代百分率和绝对数平均值都高（8．7％／6．9％和10．1／7．6），差异也有统计学意义。TP组中SDF1—3’A和CCR2V62I基因频率均高于RRP组，但差异没有统计学意义。CX3CR1 V249I／M280T与疾病快速进展没有显著相关性。结论V3区序列主要位点的氨基酸变异、Env区段糖基化程度、GA取代与疾病进展相关。SDF1—3’A、CCR2V641和CX3CR1 2491／280M与疾病进展均无显著相关性。     

河北省保定市HIV-1感染者毒株基因亚型和耐药研究

目的:了解河北省保定地区2020年全部新诊断的HIV-1感染者中,HIV-1毒株基因型和耐药发生情况。方法:使用自建的方法扩增HIV-1 pol区全长基因并测序,系统进化分析鉴定HIV-1亚型,将基因序列上传至美国斯坦福大学的HIV耐药数据库,分析耐药突变位点发生情况。 结果:共收集新诊断HIV...     

广州市吸毒强戒人员HIV-1基因亚型分布的初步研究

目的分析吸毒人群HIV感染者中HIV-1的基因序列特征,初步确定其感染的基因亚型和各亚型的流行趋势。方法在Genbank中查找HIVgag基因的序列,设计巢式PCR引物。从全血中提取样本的基因组DNA,进行巢式PCR,对PCR产物进行琼脂糖凝胶电泳和测序,所获序列与国际参考株序列进行比对,确定基因型或亚型。结果对36例HIV-1感染者样本进行扩增,PCR共检测出29例阳性样本,27例测序成功,其中16例为CRF08-BC重组亚型、7例为CRF07-BC重组亚型、4例为CRF01-AE重组亚型,15例阴性对照均无目的条带。结论在广州吸毒强戒人员HIV-1型中以CRFBC亚型为主,其次为CRF01-AE亚型。应加强对HIV-1毒株亚型的监测,以制定更好的防治策略。     

广西HIV-1重组毒株env区快速基因分型方法的建立

目的建立一种快速简便的基因分型方法，对广西HIV-1重组毒株env基因区进行亚型鉴定。方法从HIV阳性样品中提取核酸，使用HIV-1M组通用引物对env区进行第一轮扩增，第二轮则使用分别检测B′/C或C亚型和CRF01-AE亚型的二套特异性引物放入同一反应管中进行扩增，根据不同亚型扩增的目的带位置不同来判断亚型。将通用引物扩增出的所有样本均进行基因测序和系统树分析以验证结果。结果50份样本中，经基因测序和系统树分析证实CRF08-BC样本3份（6％），CRF01-AE样本43份（86％），4份（8％）样本无法确定亚型。经亚型特异性引物PCR法检测得出B′/C或C亚型样本3份（100％），CRF01-AE样本39份（90．7％），灵敏度为91．3％，特异度为100％。两种方法检测结果经差异性检验显示X^2=2．25，P〉0.05，差异无统计学意义，结果一致者占92％。与基因分析结果吻合。重复实验显示CRF08-BC平均重复性为100％（10／10），CRF01．AE为93．8％（61／65）。结论该方法是一种简便、快速、低成本，具有高度灵敏性和特异性的HIV-1毒株env基因区分型法，能够直接对广西HIV-1 CRF01-AE重组毒株进行鉴定。     

河南地区HIV-1毒株Gag基因抗原表位变异特征及准种特点研究

目的 探讨中国河南地区人免疫缺陷病毒Ⅰ型(HIV-1)毒株GAG蛋白抗原表位变异特征,并对其准种特点加以分析.方法 套式聚合酶链反应(Nested-PCR)扩增确认HIV阳性样本gagp17～p24基因区段并测序,PCR产物纯化后克隆,挑选克隆株鉴定为阳性后测序,以MEGA(version 3.0)等软件进行分析.结果 河南HIV毒株为B'亚型;gag基因p17区段抗原表位突变有E62G(55.80%),Y79F(48.90%),T84V(48.90%),144V(44.20%),gag基因p24区段抗原表位未见明显变异.结论 HIV-1 B'亚型毒株gag基因p17区段的4个抗原表位,存在较大变异,p24区段较为保守,适合抗原表位疫苗的研制.     

2006年北京市外来人口中HIV-1感染者流行毒株gag基因序列测定和亚型分析

目的了解北京市外来人口中HIV-1亚型的特点和流行规律。方法随机采集北京市2006年外来人口中新确证HIV-1感染者的抗凝全血标本80份，分离血浆，提取病毒RNA，用套式聚合酶链反应扩增病毒gag基因，并进行序列测定和亚型分析。结果系统进化分析确定北京市外来人口HIV-1毒株属于8个亚型，分别为B亚型4份，泰国B亚型15份，C亚型1份，CRF01-AE亚型5份，CRF02-AG亚型1份，CRF07-BC亚型29份，CRF08-BC亚型3份，CRFl5—01B亚型1份。结论北京市外来人口中己存在8种HIV-1亚型和流行重组型，应该加强对HIV-1亚型变异的监测。     

HIV-1 B''亚型gag-env融合基因的DNA疫苗构建和免疫原性分析

目的 构建HIV-1 B′亚型中国流行株gag和env融合基因的DNA疫苗，对其免疫原性进行研究。方法 根据已报道的HIV-1 B′亚型RIA2分离株gag和env基因的氨基酸序列按哺乳动物密码子使用频率进行优化并人工合成基因，插入真核表达载体pDRVISV1．0中，构建表达RL42 gag-env，融合蛋白的DNA疫苗，pSVRL／GE。用Western blot和抗gag p55抗体细胞内染色的方法体外检测pSVRUGE的表达效率。DNA疫苗pSVRL/GE免疫BALB／c小鼠后，用ELISPOT检测小鼠的细胞免疫反应。结果 限制性内切酶鉴定表明融合基因已成功插入pDRVISV1．0载体中，Western blot证实融合基因可有效表达融合蛋白；细胞内染色结果表明，pSVRL/GE转染的293T细胞中49．8％表达gag p55，荧光强度均值为924；而空载体pDRVISV1．0转染的293T细胞中非特异背景染色只有0．5％。经免疫的小鼠脾细胞体外用H-2^d限制性表位肽AMQMIKET刺激后，ELISPOT检测显示，pSVRUGE免疫小鼠每10^6脾细胞形成226个斑点（SD=140），而空载对照组每1驴脾细胞形成29个斑点（SD=16）（P〈0．05）。结论 所构建的DNA疫苗pSVRL/GE可高效表达相应抗原蛋白，并可有效激活机体的细胞免疫反应。     

河北省HIV-1流行株的env基因序列测定和亚型分析

目的了解河北省HIV-1亚型的分布特点和传播方式,推测流行时间,预测流行趋势。方法采集HIV感染者的全血样品,分离外周血单核细胞(PBMC),提取前病毒DNA,使用套式聚合酶链反应(nested-PCR),扩增HIV-1的env基因的C2-V3区并进行序列测定和亚型分析。结果对22份HIV-1感染者的样品,扩增得到了18份HIV-1envC2-V3基因片段,经序列测定和基因分析鉴定出3种HIV-1M亚群基因亚型,即:B′、CRF-BC和C亚型。B′亚型的组内基因离散率为7.84%±3.14%(n=14),基因序列与云南瑞丽株rl42(泰国B亚型)相近;2株CRF-BC亚型与广西毒株的基因离散率为4.60%。与血液途径感染有关的人员均为B′(泰国B)亚型。结论目前,在河北省发现了3种HIV-1亚型。输供血途径中B′亚型仍是主要的流行亚型,可能来源于云南吸毒人群。HIV-1B′亚型在河北省的流行时间大约为7~9年。     

HIV-1 Gag抗原HLA-A*0201限制性低亲和性CTL表位预测及改造分析

初步筛选HIV-1 Gag抗原的HLA-A*0201限制性低亲和性CTL表位,预测并初步鉴定修饰后的表位与HLA-A*0201之间亲和性的变化。采用超基序、蛋白酶解预测等相结合的办法筛选HLA-A*0201限制性低亲和性CTL表位,通过氨基酸置换适当修饰,并以T2细胞株测定肽与HLA-A*0201分子的亲和力和稳定性试验来评价修饰后表位与HLA-A*0201之间亲和性。结果:筛选出3个低亲和性CTL候选表位,经修饰后的表位与HLA-A*0201之间的亲和性均有不同程度的提高。YIYKRWIIL(259-267Y1),YQANFLGKI(429-437Y1)和YTNNPPIPV(249-257Y1)与HLA-A*0201呈高亲和力结合,荧光系数(flurorescene index,FI)分别为2.68、2.54和2.35,同时肽-HLA-A*0201复合物半数解离时间(dissociation complex50,DC50)均大于8h。预测的低亲和力表位经过修饰可能会成为潜在的HLA-A*0201限制性表位。     

中国HIV-1主要流行重组株B/C Tat基因第一外显子序列特征分析

目的 研究我国人类免疫缺陷病毒1型(HIV-1)流行重组株B/C Tat基因第一外显子变异特点,探讨这些变化对其功能的影响.方法 从确诊的HIV-1感染者全血样本中提取基因组DNA,经套式聚合酶链反应(PCR)扩增和测序.使用GCG和Bioedit软件中的程序进行系统进化树和氨基酸变异分析,同时进行网上三级结构预测.结果 总计154份样品中CRF07-BC为120份,CRF08-BC为34份,两种亚型有较广泛的分布,CRF07-BC与标准株的平均基因离散率为(5.748±1.352),CRF08-BC与标准株的平均基因离散率为(1.259±1.931).结论 我国流行重组株CRF07-BC比CRF08-BC有较长的流行时间,CRF07-BC与CRF08-BC基因第一外显子氨基酸相比,主要为半胱氨酸富含区和核心区的变化.在这两个区位点变化可能影响Tat与细胞因子如cyclin T1的结合能力,而成为CRF07-BC在我国流行中获得传播优势的原因.     

HIV-1 B''亚型R5或R5/X4嗜性毒株在GHOST细胞的感染性分析

目的分析我国HIV-1B′亚型R5或R5／X4嗜性毒株在GHOST细胞的感染性。方法采用传统的共培养方法从HIV-1感染者PBMC中分离并培养病毒，用表达CD4和趋化因子受体CCR5或CXCR4的GHOST细胞系，测定毒株的辅助受体利用情况，使用相同病毒量即2mg的HIV-1 p24分别感染表达不同受体的GHOST细胞系，通过流式细胞仪检测分析绿色荧光蛋白（GFP）的表达反映病毒感染细胞的能力。结果35例B′亚型毒株利用CCR5受体，占22例（62．85％），双嗜性即CCR5／CXCR4均阳性占13例（37．15％）。GHOST-R5／X4细胞的感染性分析结果显示，R5／X4双嗜性毒株的感染性明显高于CD4〉200／μl的R5毒株的感染性（P〈0．05）；R5／X4毒株与CD4≤200／μl的R5毒株感染性比较差异无统计学意义（P〉0．05）；CD4〉200／μl的R5毒株与CD4≤200／μl的R5毒株感染性比较差异有统计学意义（P〈0．05）；GHOST-CCR5细胞感染性分析结果显示：R5／X4双嗜性毒株的感染性明显下降，与CD4〉200／μl的R5毒株的感染性比较差异无统计学意义（P〉0．05）。利用相同剂量的双嗜性毒株分别感染R5、X4或R5／X4的GHOST细胞系，显示双嗜性毒株可同时利用CCR5和CXCR4辅助受体，但69．23％的R5／X4毒株以CCR5受体为主，30．77％的R5／X4毒株以CXCR4受体为主。结论HIV-1B′亚型R5／X4病毒不仅有更广泛的宿主细胞嗜性，而且在GHOST-R5／X4细胞中感染性明显提高。持续使用CCR5受体的毒株在疾病进展的过程中虽然辅助受体的利用是一样的，但病毒感染细胞的能力增加。     

HIV-1 gag基因p17+24重组抗原表达、纯化及抗原性分析

目的获得HIV-1型gag基因p17＋2，4重组抗原，分析其免疫原性和探讨开发诊断试剂的可能性。方法采用PCR技术扩增HIV-1gag基因p17＋p24核酸片段，并克隆入pTreHis2A表达质粒，在大肠杆菌BL21（DE3）株中表达。用Ni—NTA金属螯合层析法纯化目的蛋白，并用免疫印迹法分析纯化蛋白的抗原特异性。结果重组质粒在BL21（DF3）菌株中经IPm诱导表达一个相对分子质量（肘，）约为51×10^3的融合重组蛋白，重组蛋白经HIV-1p17、p24抗原单克隆抗体鉴定，具有抗原特异性。25份HIV阳性血清、180份HIV阴性血清标本初步经l临床验证，具有较高的检出敏感性和特异性。结论成功构建HIV-1型gag基因p17＋24抗原表达载体，表达纯化的p17＋24重组抗原具有较好的抗原性，可用于诊断试剂的开发。     

HIV-1中国流行株gag与hIL-2在重组痘苗病毒中的共表达及其与核酸疫苗的实验免疫研究

目的：将HIV-1中国流行株B亚型gag基因、gag和hIL-2基因在天坛株痘苗病毒中进行共表达，以期获得重组痘苗病毒，观察细胞因子的佐剂作用，与核酸疫苗混合免疫，评价免疫效果，为新型艾滋病疫苗研制开发打下基础。方法：将HIV-1中国流行株 gag基因、gag和hIL-2基因片段插入到 pJ38载体启动子下游，经同源重组和血凝素阴性空斑筛选重组痘苗病毒，SDS-PAGE、Western blot检测目的蛋白。以重组病毒和核酸疫苗免疫Balb/c小鼠，进行淋巴细胞转化实验、CTL、CD4 、CD8 T细胞数目以及血清抗体的细胞免疫和体液免疫指标检测。结果：获得了重组痘苗病毒 vJ38gag和 vJ38gag-IL-2。与 vJ38-gag相比，vJ38gag-IL-2，具有更好的免疫原性，重组痘苗病毒免疫3次的效果好于重组病毒免疫2次，以2rVV-DNA混合免疫效果最好。结论：重组痘苗病毒vJ38gag和vJ38gag-IL-2能够表达外源蛋白并诱导机体产生细胞免疫和体液免疫。细胞因子IL-2发挥了免疫佐剂的作用。     

表达HIV-1 gag基因的重组AAV2/1和Ad5疫苗免疫原性比较

目的 在小鼠体内比较表达HIT-1 gag基因的重组AAV2/1和Ad5疫苗的免疫原性.方法 分别用rAAV2/1-gag或rAd5-gag单独免疫BALB/c小鼠一次或两次,于免疫后不同时间点用CFSE染色法和胞内细胞因子染色法检测Gag特异性细胞免疫应答,用ELISA方法检测Gag特异性抗体反应.结果 单次免疫结果显示,在所有检测点rAd5-gag所诱导的Gag特异性CTL应答都比rAAV2/1-gag强,抗体反应在免疫后4周无明显差异.两次免疫后4周的检测结果表明,rAd5-gag所诱导的Gag特异性CTL应答比rAAV2/1-gag强,但抗体反应比rAAV2/1-gag组弱.结论 rAd5-gag诱导了很好的HIV-1特异性细胞和抗体反应,而rAAV2/1-gag诱导的HIV-1特异性抗体反应很强,但细胞免疫应答较弱.     

The affinity of IgG antibodies to gag p24 and p17 in HIV-1-infected patients correlates with disease progression.

The affinity of anti-gag antibody was studied for up to 9 years (1984-1993) in sera from 15 HIV-1+ patients with haemophilia. On the basis of their 1993 clinical status patients were divided into two groups: (i) patients who remained asymptomatic (n = 9); and (ii) those who progressed to AIDS between late 1987 and 1993. The affinity constants of antibody for p24 and p17 were determined by a double isotope fluid-phase radioimmunoassay; and the relationships between antibody affinity and titre, patient clinical course, CD4 cell counts and p24 antigenaemia were analysed. The affinity of p24- and p17-specific antibody was up to 100 times greater in asymptomatic patients than in patients who progressed to AIDS. Patients who developed AIDS either lost or failed to develop high-affinity antibodies early in the infection. Asymptomatic patients maintained high-affinity antibodies for several years; however, in some of these patients the affinity of anti-p24 and p17 antibodies subsequently fell later in the study period. The presence of low-affinity antibody and progressive reduction in the titre of specific antibody were earlier predictors of disease onset than CD4 cell counts. The failure to either develop or maintain high affinity gag-specific antibody suggests an early impairment of T helper function in individuals who progressed to AIDS. The presence of antibody of high affinity could be essential in controlling virus replication and the onset of AIDS.     

Immunogenicity of the recombinant adenovirus type 5 vector with type 35 fiber containing HIV-1 gag gene

The immune efficiency of a recombinant adenovirus type 5 with type 35 fiber containing HIV-1 gag gene (rAd5/F35-mod.gag) was investigated in BALB/c mice, in which the rAd5/F35-mod.gag was firstly identified with PCR, then transfected to 293 cells and the in vitro expression level of Gag protein was determined by Western blotting and indirect immuno-fluorescent assay. Mice were immunized with intramuscular injections of rAd5/F35-mod.gag, rAd5-mod.gag or DNA and were boosted after 3 weeks. To test the effect of pre-existing anti-viral immunity on immunization, mice were also injected with Ad5-GFP vector and then immunized 4 and 7 weeks later with Ad5/F35-mod. gag vector. The P24-specific IgG antibody in sera of immunized mice was determined by ELISA and the specific cytotoxic T lymphocyte (CTL) response was assayed by intracellular cytokine staining. It was demonstrated that the rAd5/F35-mod. gag vector could express efficiently the HIV Gag protein in 293 cells in vitro and induce strong HIV-specific immune responses in vivo. The strongest CTL and serum IgG response occurred when mice were immunized twice with injection of rAd5/F35 alone, but the anti-Ad5 antibody after primary infection with adenovirus could inhibit the specific immune responses induced by rAd5/F35 vector. It is concluded that single immunization with recombinant adenovirus rAd5/F35-mod. gag can induce specific CTL and serum IgG antibody responses in mice, but the immunogenicity of rAd5/F35 is comparably weaker than that of rAd5.     

Ancestral and consensus envelope immunogens for HIV-1 subtype C

Immunogens based on "centralized" (ancestral or consensus) HIV-1 sequences minimize the genetic distance between vaccine strains and contemporary viruses and should thus elicit immune responses that recognize a broader spectrum of viral variants. However, the biologic, antigenic and immunogenic properties of such inferred gene products have to be validated experimentally. Here, we report the construction and characterization of the first full-length ancestral (AncC) and consensus (ConC) env genes of HIV-1 (group M) subtype C. The codon-usage-optimized genes expressed high levels of envelope glycoproteins that were incorporated into HIV-1 virions, mediated infection via the CCR5 co-receptor and retained neutralizing epitopes as recognized by plasma from patients with chronic HIV-1 subtype C infection. Guinea pigs immunized with AncC and ConC env DNA developed high titer binding, but no appreciable homologous or heterologous neutralizing antibodies. When tested by immunoblot analysis, sera from AncC and ConC env immunized guinea pigs recognized a greater number of primary subtype C envelope glycoproteins than sera from guinea pigs immunized with a contemporary subtype C env control. Mice immunized with AncC and ConC env DNA developed gamma interferon T cell responses that recognized overlapping peptides from the cognate ConC and a heterologous subtype C Env control. Thus, both AncC and ConC env genes expressed functional envelope glycoproteins that were immunogenic in laboratory animals and elicited humoral and cellular immune responses of comparable breadth and magnitude. These results establish the utility of centralized HIV-1 subtype C Env immunogens and warrant their continued evaluation as potential components of future AIDS vaccines.     

T cell responses to peptides covering the gag p24 region of HIV-1 occur in HIV-1 seronegative individuals.

We demonstrate that peptides (16 amino acids long) covering the sequence of the HIV-1 core protein p24 induce significant proliferation in peripheral blood mononuclear cells (PBMC) of several (greater than 50%) healthy seronegative volunteers as well as seronegative homosexual men. The nature of this response was characterized and compared with those of HIV-infected patients. Several peptides induced responses; however, the most frequent responses in both seropositive and seronegative individuals were noted to the following peptides: 1 and 2 (aa 133-157); 6 and 7 (aa 183-207); 15 (aa 273-287); and 17 and 18 (aa 293-317). The response pattern was related to the disease stage of the patients; seronegative individuals as well as asymptomatic seropositive individuals (CDC II/III) responded to low concentrations of several peptides, but symptomatic patients (CDC IV) only responded to high concentrations of a few peptides. Cell separation studies of PBMC from healthy volunteers showed that the responding cells were CD4+ and expressed the CD45RO differentiation antigen. Furthermore, cord-blood mononuclear cells with less than 5% of CD45RO T cells did not proliferative to any of the peptides. Finally, CD4+ T cell lines specific for both peptides and p24 protein were successfully established from the PBMC of seronegative individuals confirming the data obtained with freshly isolated cells. These studies therefore suggest that the CD4+ cell response to p24 is not strictly disease related, instead, the response may be due to priming of the host with cross-reactive antigens.     

Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins

"Centralized" (ancestral and consensus) HIV-1 envelope immunogens induce broadly cross-reactive T cell responses in laboratory animals; however, their potential to elicit cross-reactive neutralizing antibodies has not been fully explored. Here, we report the construction of a panel of consensus subtype B (ConB) envelopes and compare their biologic, antigenic, and immunogenic properties to those of two wild-type Env controls from individuals with early and acute HIV-1 infection. Glycoprotein expressed from full-length (gp160), uncleaved (gp160-UNC), truncated (gp145), and N-linked glycosylation site deleted (gp160-201N/S) versions of the ConB env gene were packaged into virions and, except for the fusion defective gp160-UNC, mediated infection via the CCR5 co-receptor. Pseudovirions containing ConB Envs were sensitive to neutralization by patient plasma and monoclonal antibodies, indicating the preservation of neutralizing epitopes found in contemporary subtype B viruses. When used as DNA vaccines in guinea pigs, ConB and wild-type env immunogens induced appreciable binding, but overall only low level neutralizing antibodies. However, all four ConB immunogens were significantly more potent than one wild-type vaccine at eliciting neutralizing antibodies against a panel of tier 1 and tier 2 viruses, and ConB gp145 and gp160 were significantly more potent than both wild-type vaccines at inducing neutralizing antibodies against tier 1 viruses. Thus, consensus subtype B env immunogens appear to be at least as good as, and in some instances better than, wild-type B env immunogens at inducing a neutralizing antibody response, and are amenable to further improvement by specific gene modifications.